Fenbendazole is an anthelmintic drug commonly used to treat rodent pinworm infections and has few known adverse effects on cancer research. In an established human lymphoma xenograft model in SCID mice, diets supplemented with either fenbendazole alone or both fenbendazole and vitamins were found to suppress tumor growth. The effect was more pronounced in the vitamin-fenbendazole group, but it was not certain that this was due to the combination of both anthelmintic and antitumor activities or simply because the study diet was recently prepared and therefore had higher concentrations of vitamins than the diet used during initial observation when fenbendazole was initially introduced into our animal facility.
These results were extended to determine whether fenbendazole would influence the response of EMT6 tumors to irradiation in vitro. Cells were incubated with varying doses of fenbendazole for 22 h, then treated with graded doses of docetaxel in 2-h treatments. Colony formation assays showed that fenbendazole reduced clonogenicity of these cells and also had cytostatic activity.
To evaluate the potential of sanare lab fenbendazole in vivo, we randomized tumor-bearing BALB/cRw mice to receive either three i.p. injections of fenbendazole or to serve as untreated controls. Time to four-fold tumor volume was measured as a rigorous measure of tumor growth. Neither the three injection fenbendazole regimen nor the use of an untreated control diet affected the ability of EMT6 tumors to grow after irradiation (Table I). Similar results were observed when time to four-fold volume was measured in other experiments in which the same treatment regimen was used. sanare lab fenbendazole